← Leaderboards
Rozalina Grubina McCoy
Mayo Clinic Rochester
$3,562,219
Attributed
$5,824,747
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,288,065 · 7
By mechanism
R01$4,525,056 · 3
K23$846,296 · 1
P30$678,213 · 2
R03$238,500 · 1
Top collaborators
- Juan P Brito Campana4 shared
- David Eric Arterburn2 shared
- Jie Chen1 shared
- Kasia Joanna Lipska1 shared
- Stephen B. Thomas1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Martin Ernesto Fernandez-Zapico$10,185,222
- Juan P Brito Campana$3,769,661
- Dennis M Black$9,656,727
- Aivi Thanh Nguyen$311,040
- Asghar Rezaei$737,209
Others in their field
Other Emerging Leaders on “Hospitalization”
- Beth Baseler · Leidos Biomedical Research, Inc.$105,136,677
- Ted Ross · University Of Georgia$68,763,143
- Abraham Aizer Brody · New York University School Of Medicine$40,089,349
- Xinhua Li · Nano Terra, Inc.$32,991,103
- James Dale Berry · Brigham And Women'S Hospital$20,824,388
- Tareq Al Baghdadi · Saint Joseph Mercy Health System$19,225,531
Research focus
HospitalizationMultidisciplinaryPreventCaringHigh RiskPatient CareAdultPatient OrientedQuality Of LifeElectronic Health RecordImpairmentDiabetes MellitusHypoglycemiaCostGlycemic ControlHeterogeneityHyperglycemiaData SetLeadData WarehouseEventAffectMortalityAmerican
Grant awards (16)
Comparative Effectiveness and Safety of Osteoporosis Drug Therapies$810,627
R01 · FY2025 · AG
"Insulin Affordability: Unpacking the Impact of the Inflation Reduction Act on Diabetes Outcomes in Medicare."$749,566
R01 · FY2025 · DK
Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes$660,172
R01 · FY2025 · DK
Center for Seniors Uniting Nationwide to Support Health, INtegrated care, and Economics (SUNSHINE)$463,318
P30 · FY2025 · AG
Program Development (Pilot) Core (Core B)$214,895
P30 · FY2025 · AG · contact PI
Comparative Effectiveness and Safety of Metabolic/Bariatric Surgery, GLP-1, and SGLT-2 Medications for Patients with Obesity and Type 2 Diabetes$696,763
R01 · FY2024 · DK
Comparative Effectiveness and Safety of Osteoporosis Drug Therapies$545,907
R01 · FY2024 · AG
Comparative Effectiveness and Safety of Osteoporosis Drug Therapies$530,459
R01 · FY2023 · AG
Comparative Effectiveness and Safety of Osteoporosis Drug Therapies$531,562
R01 · FY2022 · AG
Community Paramedicine Program to Improve Diabetes Management among Adults Experiencing Severe Hypoglycemia$119,250
R03 · FY2022 · DK · contact PI
Predicting the Risk of Severe Hypoglycemic and Hyperglycemic Events in Adults with Diabetes$168,817
K23 · FY2021 · DK · contact PI
Community Paramedicine Program to Improve Diabetes Management among Adults Experiencing Severe Hypoglycemia$119,250
R03 · FY2021 · DK · contact PI
Predicting the Risk of Severe Hypoglycemic and Hyperglycemic Events in Adults with Diabetes$169,005
K23 · FY2020 · DK · contact PI
Predicting the Risk of Severe Hypoglycemic and Hyperglycemic Events in Adults with Diabetes$168,896
K23 · FY2019 · DK · contact PI
Predicting the Risk of Severe Hypoglycemic and Hyperglycemic Events in Adults with Diabetes$169,112
K23 · FY2018 · DK · contact PI
Predicting the Risk of Severe Hypoglycemic and Hyperglycemic Events in Adults with Diabetes$170,466
K23 · FY2017 · DK · contact PI